

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
**WO 2004/006851 A2**

(51) International Patent Classification<sup>7</sup>:

**A61K**

(74) Agent: GLASGOW, JINan; Glasgow Law Firm, PLLC,  
P.O. Box 28539, Raleigh, NC 27611-8539 (US).

(21) International Application Number:

PCT/US2003/022011

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 10 July 2003 (10.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/194,180 13 July 2002 (13.07.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; 630 Boyd Graduate Studies Research Center, Athens, GA 30602 (US).

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/006851 A2

(54) Title: **MYCOPLASMA GALLISEPTICUM FORMULATION**

(57) **Abstract:** The present invention provides a protective formulation that prevents virulent *Mycoplasma gallisepticum* infection in birds of the order Galliformes. The formulation comprises a protective amount of live MG strain K5054 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent *Mycoplasma gallisepticum* infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.